Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hyoscine N-butylbromide versus lidocaine for prevention of propofol injection pain
IRCT20190109042309N2Phase 3Completed
- Sponsor
- Sabzevar University of Medical Sciences
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of hyoscine butylbromide, lidocaine and propofol in Not applicable (2 arms), sponsored by Sabzevar University of Medical Sciences. Primary endpoint: Intensity of pain. Started Feb 2019; status: completed.
02
Drugs
hyoscine butylbromidelidocainepropofol
03
Conditions
Not applicable
Beyond the preview
Go deeper on IRCT20190109042309N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20190109042309N2.